Longevity Science × Macro-Finance

The intelligence layer between peer-reviewed research and wealth preservation.

Salus Vantage synthesizes outlier findings from global research databases and central bank bulletins into actionable executive briefs. No hype. No supplements to sell. Every claim cited, every source credible, every insight built for people who make consequential decisions.

Sample Executive Brief
Rapamycin Dosing Protocols & Portfolio Implications for Longevity-Linked Biotech
Key finding: Phase II data shows 12% improvement in immune response markers at intermittent low-dose protocols vs. continuous dosing.
Wealth signal: Three publicly traded biotech firms hold IP on mTOR-pathway modulators. Two are undervalued relative to pipeline depth.
Sources: Nature Medicine • J.P. Morgan Healthcare • NIH Clinical Trials Registry
Four Pillars

Where the research converges, the vantage point emerges.

I

Longevity Science

Scanning PubMed, NIH, CIHR, Nature Medicine, JAMA, and Science for outlier data on healthspan extension, cellular senescence, metabolic interventions, and anticipatory diagnostics.

II

Macro-Finance

Monitoring Federal Reserve bulletins, central bank policy shifts, J.P. Morgan Private Bank research, and Oliver Wyman reports for wealth-preservation signals that intersect with health economics.

III

Health Economics

Translating clinical trial outcomes into market intelligence. When a longevity intervention shows Phase III promise, the portfolio implications arrive in your inbox before the headlines.

IV

Wealth Preservation

Synthesizing longevity-adjusted financial planning, insurance actuarial shifts, and the compounding value of healthspan on multi-decade wealth strategies.

The Cycle

Every night, while markets sleep.

Phase I: Scan

Global Database Sweep

Automated research scan across PubMed, NIH, central bank bulletins, and financial databases for outlier data impacting healthspan or wealth preservation.

Phase II: Synthesize

Executive-Level Analysis

Complex findings distilled into clear executive summaries. Every claim backed by cited, peer-reviewed sources. No PhD required to understand the implications.

Phase III: Deliver

Multi-Channel Distribution

Weekly deep-dive newsletter, data-driven video analyses, and LinkedIn intelligence drops. Research reaches you where you already are, in the format you prefer.

Editorial Standards

The anti-hype protocol.

Citation-First Publishing

Every claim traces back to a credible, verifiable source. No anonymous experts, no "studies show" without the study. The citation is the product.

Forbidden Language

Words like "miracle," "shocking," "guaranteed," and "breakthrough" are banned from our vocabulary. Clinical accuracy, sophisticated tone, authoritative delivery.

Accessible Rigor

Complex data translated into executive summaries that respect your intelligence without requiring your specialization. The synthesis is the value.

Trusted Sources

PubMed NIH CIHR Nature Medicine JAMA Science Nature Federal Reserve Harvard Health Stanford Lifestyle Medicine J.P. Morgan Oliver Wyman Blue Zones NIST

Researcher-Led Curation

Founded by a researcher with 160+ peer-reviewed publications, a Presidential Early Career Award, and editorial leadership at IEEE and Biomedical Engineering Online. This is not content marketing. This is research communication.

The longest-living, most financially secure individuals are not the best informed. They are the best synthesized.

Salus Vantage exists because the gap between published research and applied intelligence should not require a medical degree and a Bloomberg terminal to bridge.